Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - AB 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 116275.37 
• Atom Count: 7123 
• Residue Count: 1000 
• Unique protein chains: 2

1C0T

CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH BM+21.1326

• DOI: 10.2210/pdb1C0T/pdb

• Classification: TRANSFERASE
• Organism(s): Human immunodeficiency virus type 1 group M subtype B
• Expression System: Escherichia coli


• Deposited: 1999-07-19 Released: 2000-07-19 
• Deposition Author(s): Ren, J., Esnouf, R.M., Hopkins, A.L., Stuart, D.I., Stammers, D.K.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.7 Å
• R-Value Free: 0.276 
• R-Value Work: 0.214 

Literature

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.

Ren, J., Esnouf, R.M., Hopkins, A.L., Stuart, D.I., Stammers, D.K.

(1999) J.Med.Chem. 42: 3845-3851

• PubMed: 10508433 
• Primary Citation of Related Structures:  
  1C0U
• Also Cited By: 1DTT, 1DTQ


• PubMed Abstract: 
  

We have determined the crystal structures of thiazoloisoindolinone non-nucleoside inhibitors in complex with HIV-1 reverse transcriptase to high-resolution limits of 2.7 A (BM +21.1326) and 2. 52 A (BM +50.0934). We find that the binding modes of this series of inhibitors closely resemble that of "two-ring" non-nucleoside reverse transcriptase inhibitors. The structures allow rationalization of stereochemical requirements, structure-activity data, and drug resistance data. Comparisons with our previous structures suggest modifications to the inhibitors that might improve resilience to drug-resistant mutant forms of reverse transcriptase. Comparison with earlier modeling studies reveals that the predicted overlap of thiazoloisoindolinones with TIBO was largely correct, while that with nevirapine was significantly different.

---

Related Citations: 

• The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design
  Ren, J.,Esnouf, R.M.,Hopkins, A.L.,Ross, C.K.,Jones, E.Y.,Stammers, D.K.,Stuart, D.I.
  (1995) Structure 3: 915
• Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives
  Ren, J.,Esnouf, R.M.,Hopkins, A.L.,Warren, J.,Balzarini, J.,Stuart, D.I.,Stammers, D.K.
  (1998) Biochemistry 37: 14394
• Crystals of HIV-1 Reverse Transcriptase Diffracting to 2.2 Angstrom Resolution
  Stammers, D.K.,Somers, D.O.,Ross, C.K.,Kirby, I.,Ray, P.H.,Wilson, J.E.,Norman, M.,Ren, J.,Esnouf, R.M.,Garman, E.,Jones, E.Y.,Stuart, D.I.
  (1994) J.Mol.Biol. 242: 586
• Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors
  Hopkins, A.L.,Ren, J.,Esnouf, R.M.,Willcox, B.E.,Jones, E.Y.,Ross, C.K.,Miyasaka, T.,Walker, R.T.,Tanaka, H.,Stammers, D.K.,Stuart, D.I.
  (1996) J.Med.Chem. 39: 1589
• Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this non-nucleoside inhibitor
  Esnouf, R.M.,Ren, J.,Hopkins, A.L.,Ross, C.K.,Jones, E.Y.,Stammers, D.K.,Stuart, D.I.
  (1997) Proc.Natl.Acad.Sci.USA 94: 3984
• 3'-azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes
  Ren, J.,Esnouf, R.M.,Hopkins, A.L.,Jones, E.Y.,Kirby, I.,Keeling, J.,Ross, C.K.,Larder, B.A.,Stuart, D.I.,Stammers, D.K.
  (1998) Proc.Natl.Acad.Sci.USA 95: 9518
• Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration
  Esnouf, R.M.,Ren, J.,Garman, E.,Somers, D.O.,Ross, C.K.,Jones, E.Y.,Stammers, D.K.,Stuart, D.I.
  (1998) Acta Crystallogr.,Sect.D 54: 938
• Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Non-nucleoside Inhibitors
  Esnouf, R.M.,Ren, J.,Ross, C.K.,Jones, E.Y.,Stammers, D.K.,Stuart, D.I.
  (1995) Nat.Struct.Mol.Biol. 2: 303
• High Resolution Structures of HIV-1 RT From Four RT-inhibitor Complexes
  Ren, J.,Esnouf, R.M.,Garman, E.,Somers, D.O.,Ross, C.K.,Kirby, I.,Keeling, J.,Darby, G.,Jones, E.Y.,Stuart, D.I.,Stammers, D.K.
  (1995) Nat.Struct.Mol.Biol. 2: 293




---

Organizational Affiliation: 

Laboratory of Molecular Biophysics, Rex Richards Building, South Parks Road, Oxford OX1 3QU, U.K..

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
HIV-1 REVERSE TRANSCRIPTASE (A-CHAIN)	A	560	Human immunodeficiency virus type 1 group M subtype B	Mutation(s): 0  Gene Names: gag-pol
Find proteins for P04585 (Human immunodeficiency virus type 1 group M subtype B) Go to UniProtKB:  P04585

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
HIV-1 REVERSE TRANSCRIPTASE (B-CHAIN)	B	440	Human immunodeficiency virus type 1 group M subtype B	Mutation(s): 0  Gene Names: gag-pol
Find proteins for P04585 (Human immunodeficiency virus type 1 group M subtype B) Go to UniProtKB:  P04585

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
BM1	A	(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE BM+21.1326 C17 H15 N O S FQVDJZWFSZSGGA-QGZVFWFLSA-N

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
CSD	A	L-PEPTIDE LINKING	C3 H7 N O4 S		CYS

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
BM1	IC50: 30 - 35 nM (99) BINDINGDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.7 Å
• R-Value Free: 0.276 
• R-Value Work: 0.214 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 135.100	α = 90.00
b = 112.700	β = 90.00
c = 75.100	γ = 90.00

Software Package:

Software Name	Purpose
X-PLOR	model building
DENZO	data reduction
X-PLOR	phasing
CNS	refinement
SCALEPACK	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 1999-07-19 
• Released Date: 2000-07-19 
• Deposition Author(s): Ren, J., Esnouf, R.M., Hopkins, A.L., Stuart, D.I., Stammers, D.K.

Revision History 

• Version 1.0: 2000-07-19
  Type: Initial release
• Version 1.1: 2008-04-27
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance
• Version 1.3: 2014-11-12
  Type: Non-polymer description